Literature DB >> 27039393

Peanut Allergy: New Developments and Clinical Implications.

Scott P Commins1,2,3,4, Edwin H Kim5,6,7, Kelly Orgel7, Mike Kulis7.   

Abstract

Food allergies have increased in prevalence over the past 20 years, now becoming an important public health concern. Although there are no therapies currently available for routine clinical care, recent reports have indicated that immunotherapies targeting the mucosal immune system may be effective. Oral immunotherapy is conducted by administering small, increasing amounts of food allergen; it has shown promise for desensitizing individuals with peanut, egg, or milk allergies. Sublingual immunotherapy also desensitizes allergic patients to foods-two major studies have examined the effects of sublingual immunotherapy in subjects with peanut allergies. We review the complex nature of IgE-mediated food allergies and the therapies being evaluated in clinical trials. We focus on the diagnosis and management of food allergies and investigational therapies.

Entities:  

Keywords:  Anaphylaxis; Food allergy; IgE; Peanut allergy

Mesh:

Substances:

Year:  2016        PMID: 27039393     DOI: 10.1007/s11882-016-0613-x

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  16 in total

1.  Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization.

Authors:  Edwin H Kim; J Andrew Bird; Michael Kulis; Susan Laubach; Laurent Pons; Wayne Shreffler; Pamela Steele; Janet Kamilaris; Brian Vickery; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2011-02-01       Impact factor: 10.793

2.  A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.

Authors:  Lynda C Schneider; Rima Rachid; Jennifer LeBovidge; Emily Blood; Mudita Mittal; Dale T Umetsu
Journal:  J Allergy Clin Immunol       Date:  2013-10-28       Impact factor: 10.793

3.  Oral peanut immunotherapy in children with peanut anaphylaxis.

Authors:  Katharina Blumchen; Helen Ulbricht; Ute Staden; Kerstin Dobberstein; John Beschorner; Lucila Camargo Lopes de Oliveira; Wayne G Shreffler; Hugh A Sampson; Bodo Niggemann; Ulrich Wahn; Kirsten Beyer
Journal:  J Allergy Clin Immunol       Date:  2010-06-12       Impact factor: 10.793

4.  Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome.

Authors:  K Anagnostou; A Clark; Y King; S Islam; J Deighton; P Ewan
Journal:  Clin Exp Allergy       Date:  2011-03-18       Impact factor: 5.018

5.  A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.

Authors:  Pooja Varshney; Stacie M Jones; Amy M Scurlock; Tamara T Perry; Alex Kemper; Pamela Steele; Anne Hiegel; Janet Kamilaris; Suzanne Carlisle; Xiaohong Yue; Mike Kulis; Laurent Pons; Brian Vickery; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

6.  A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.

Authors:  Satya D Narisety; Pamela A Frischmeyer-Guerrerio; Corinne A Keet; Mark Gorelik; John Schroeder; Robert G Hamilton; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2014-12-18       Impact factor: 10.793

7.  Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy.

Authors:  L Mondoulet; V Dioszeghy; M Ligouis; V Dhelft; C Dupont; P-H Benhamou
Journal:  Clin Exp Allergy       Date:  2009-12-10       Impact factor: 5.018

8.  Clinical efficacy and immune regulation with peanut oral immunotherapy.

Authors:  Stacie M Jones; Laurent Pons; Joseph L Roberts; Amy M Scurlock; Tamara T Perry; Mike Kulis; Wayne G Shreffler; Pamela Steele; Karen A Henry; Margaret Adair; James M Francis; Stephen Durham; Brian P Vickery; Xiaoping Zhong; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-07-03       Impact factor: 10.793

9.  Safety of a peanut oral immunotherapy protocol in children with peanut allergy.

Authors:  Alison M Hofmann; Amy M Scurlock; Stacie M Jones; Kricia P Palmer; Yuliya Lokhnygina; Pamela H Steele; Janet Kamilaris; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-05-27       Impact factor: 10.793

10.  Oral desensitizing treatment in food allergy: clinical and immunological results.

Authors:  G Patriarca; E Nucera; C Roncallo; E Pollastrini; F Bartolozzi; T De Pasquale; A Buonomo; G Gasbarrini; C Di Campli; D Schiavino
Journal:  Aliment Pharmacol Ther       Date:  2003-02       Impact factor: 8.171

View more
  2 in total

1.  Antigenic cross-reactivity between Schistosoma mansoni and peanut: a role for cross-reactive carbohydrate determinants (CCDs) and implications for the hygiene hypothesis.

Authors:  Joseph E Igetei; Marwa El-Faham; Susan Liddell; Michael J Doenhoff
Journal:  Immunology       Date:  2017-02-15       Impact factor: 7.397

2.  Lactobacillus buchneri S-layer as carrier for an Ara h 2-derived peptide for peanut allergen-specific immunotherapy.

Authors:  Julia Anzengruber; Merima Bublin; Eva Bönisch; Bettina Janesch; Angelika Tscheppe; Matthias L Braun; Eva-Maria Varga; Christine Hafner; Heimo Breiteneder; Christina Schäffer
Journal:  Mol Immunol       Date:  2017-02-14       Impact factor: 4.407

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.